Yahoo
NasdaqGS - Nasdaq Real Time Price USD

SpyGlass Pharma, Inc. (SGP)

34.45 +0.81 (+2.41%)
At close: 4:00:00 PM EST
34.45 0.00 (0.00%)
After hours: 4:00:10 PM EST
Chart Range Bar
Loading chart for SGP
  • Previous Close 33.64
  • Open 34.08
  • Bid 24.81 x 200
  • Ask 34.57 x 100
  • Day's Range 34.08 - 35.15
  • 52 Week Range 17.06 - 35.15
  • Volume 191,537
  • Avg. Volume 102,062
  • Market Cap (intraday) 1.152B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.51
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 44.00
  • Zacks Rating Neutral

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

www.spyglasspharma.com

76

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SGP
43.54%
S&P 500 (^GSPC)
10.57%

1-Year Return

SGP
43.54%
S&P 500 (^GSPC)
10.46%

3-Year Return

SGP
43.54%
S&P 500 (^GSPC)
73.67%

5-Year Return

SGP
43.54%
S&P 500 (^GSPC)
62.40%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -19.86M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

37.00
44.00 Average
34.45 Current
62.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/21/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 37 -> 37

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -56.05M

  • Diluted EPS (ttm)

    -2.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    234.19M

  • Total Debt/Equity (mrq)

    0.70%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: